Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
Catalyst Biosciences, Inc.
Develops therapeutics for hemophilia and inflammatory diseases
Transaction Summary
Completed reverse merger with Targacept in August 2015
Catalyst is the surviving public entity now trading on the NASDAQ as "CBIO"
Lead product, a Factor VIIa drug candidate for hemophilia, has successfully completed Phase I trials
Catalyst is well-capitalized to advance its hemophilia drug into pivotal clinical trials
South San Francisco, CA
NASDAQ: CBIO
Contact:
Jeff Himawan
www.catalystbiosciences.com
Related News
Targacept and Catalyst Biosciences Enter Definitive Merger Agreement
Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
Catalyst Biosciences Announces Agreement with MedImmune to Develop Engineered Protease Therapeutics